Overview
Carcinosarcoma of the cervix uteri, also known as malignant mixed Müllerian tumor (MMMT) of the cervix, is an extremely rare and aggressive malignant neoplasm arising in the uterine cervix. This tumor is classified as a biphasic neoplasm, meaning it contains both malignant epithelial (carcinomatous) and malignant mesenchymal (sarcomatous) components. The carcinomatous element is most often squamous cell carcinoma or adenocarcinoma, while the sarcomatous component may be homologous (e.g., fibrosarcoma, leiomyosarcoma) or heterologous (e.g., containing cartilage, bone, or skeletal muscle differentiation such as rhabdomyosarcoma or chondrosarcoma). The disease primarily affects the female reproductive system, specifically the cervix. Patients typically present with abnormal vaginal bleeding (postmenopausal or intermenstrual), a cervical mass or polypoid growth protruding from the cervical os, pelvic pain, and vaginal discharge. Due to its aggressive nature, the tumor tends to grow rapidly and may invade surrounding pelvic structures, with a propensity for both local recurrence and distant metastasis to the lungs, liver, and lymph nodes. Most cases are diagnosed in postmenopausal women, though cases in younger women have been reported. Given its rarity, there are no standardized treatment protocols, and management is largely extrapolated from experience with uterine carcinosarcomas and cervical carcinomas. Treatment typically involves radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph node dissection when feasible. Adjuvant therapy, including platinum-based chemotherapy and/or pelvic radiation therapy, is frequently employed, particularly in advanced-stage disease. Despite multimodal treatment, the prognosis remains poor, with high rates of recurrence and a generally unfavorable overall survival compared to conventional cervical carcinomas. Early-stage detection and complete surgical resection offer the best chance for improved outcomes.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Carcinosarcoma of the cervix uteri.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Carcinosarcoma of the cervix uteri at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Carcinosarcoma of the cervix uteri.
Community
No community posts yet. Be the first to share your experience with Carcinosarcoma of the cervix uteri.
Start the conversation →Latest news about Carcinosarcoma of the cervix uteri
Disease timeline:
New recruiting trial: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
A new clinical trial is recruiting patients for Carcinosarcoma of the cervix uteri
New recruiting trial: Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
A new clinical trial is recruiting patients for Carcinosarcoma of the cervix uteri
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Carcinosarcoma of the cervix uteri
What is Carcinosarcoma of the cervix uteri?
Carcinosarcoma of the cervix uteri, also known as malignant mixed Müllerian tumor (MMMT) of the cervix, is an extremely rare and aggressive malignant neoplasm arising in the uterine cervix. This tumor is classified as a biphasic neoplasm, meaning it contains both malignant epithelial (carcinomatous) and malignant mesenchymal (sarcomatous) components. The carcinomatous element is most often squamous cell carcinoma or adenocarcinoma, while the sarcomatous component may be homologous (e.g., fibrosarcoma, leiomyosarcoma) or heterologous (e.g., containing cartilage, bone, or skeletal muscle differe
How is Carcinosarcoma of the cervix uteri inherited?
Carcinosarcoma of the cervix uteri follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Carcinosarcoma of the cervix uteri typically begin?
Typical onset of Carcinosarcoma of the cervix uteri is adult. Age of onset can vary across affected individuals.
Which specialists treat Carcinosarcoma of the cervix uteri?
3 specialists and care centers treating Carcinosarcoma of the cervix uteri are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.